Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome)

Daniel O. Clegg, Domenic J. Reda, Michael H. Weisman, John J. Cush, Frank B. Vasey, H. Ralph Schumacher, Elly Budiman-Mak, Dominic J. Balestra, Warren D. Blackburn, Grant W. Cannon, Robert D. Inman, F. Paul Alepa, Edwin Mejias, Miriam R. Cohen, Rama Makkena, Maren L. Mahowald, Jean Higashida, Stuart L. Silverman, Nourollah Parhami, Joel BuxbaumClair M. Haakenson, Richard H. Ward, B. J. Manaster, Robert J. Anderson, John R. Ward, William G. Henderson

Research output: Contribution to journalReview article

Abstract

Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective in the treatment of reactive arthritis (ReA) that has been unresponsive to nonsteroidal antiinflammatory drug (NSAID) therapy. Methods. One hundred thirty-four patients with ReA who had failed to respond to NSAIDs were recruited from 19 clinics, randomized (double-blind) to receive either SSZ or placebo, and followed up for 36 weeks. The definition of treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed improvement in the patients taking SSZ compared with those taking placebo, which appeared at 4 weeks and continued through the trial (P = 0.02). At the end of treatment, response rates were 62.3% for SSZ treatment compared with 47.7% for placebo treatment. The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and effective in patients with chronically active ReA.

Original languageEnglish (US)
Pages (from-to)2021-2027
Number of pages7
JournalArthritis and Rheumatism
Volume39
Issue number12
StatePublished - Dec 1996
Externally publishedYes

Fingerprint

Reactive Arthritis
Sulfasalazine
Placebos
Therapeutics
Blood Sedimentation
Arthralgia
Non-Steroidal Anti-Inflammatory Agents
Anti-Inflammatory Agents
Physicians
Drug Therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Clegg, D. O., Reda, D. J., Weisman, M. H., Cush, J. J., Vasey, F. B., Schumacher, H. R., ... Henderson, W. G. (1996). Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). Arthritis and Rheumatism, 39(12), 2021-2027.

Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). / Clegg, Daniel O.; Reda, Domenic J.; Weisman, Michael H.; Cush, John J.; Vasey, Frank B.; Schumacher, H. Ralph; Budiman-Mak, Elly; Balestra, Dominic J.; Blackburn, Warren D.; Cannon, Grant W.; Inman, Robert D.; Alepa, F. Paul; Mejias, Edwin; Cohen, Miriam R.; Makkena, Rama; Mahowald, Maren L.; Higashida, Jean; Silverman, Stuart L.; Parhami, Nourollah; Buxbaum, Joel; Haakenson, Clair M.; Ward, Richard H.; Manaster, B. J.; Anderson, Robert J.; Ward, John R.; Henderson, William G.

In: Arthritis and Rheumatism, Vol. 39, No. 12, 12.1996, p. 2021-2027.

Research output: Contribution to journalReview article

Clegg, DO, Reda, DJ, Weisman, MH, Cush, JJ, Vasey, FB, Schumacher, HR, Budiman-Mak, E, Balestra, DJ, Blackburn, WD, Cannon, GW, Inman, RD, Alepa, FP, Mejias, E, Cohen, MR, Makkena, R, Mahowald, ML, Higashida, J, Silverman, SL, Parhami, N, Buxbaum, J, Haakenson, CM, Ward, RH, Manaster, BJ, Anderson, RJ, Ward, JR & Henderson, WG 1996, 'Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome)', Arthritis and Rheumatism, vol. 39, no. 12, pp. 2021-2027.
Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). Arthritis and Rheumatism. 1996 Dec;39(12):2021-2027.
Clegg, Daniel O. ; Reda, Domenic J. ; Weisman, Michael H. ; Cush, John J. ; Vasey, Frank B. ; Schumacher, H. Ralph ; Budiman-Mak, Elly ; Balestra, Dominic J. ; Blackburn, Warren D. ; Cannon, Grant W. ; Inman, Robert D. ; Alepa, F. Paul ; Mejias, Edwin ; Cohen, Miriam R. ; Makkena, Rama ; Mahowald, Maren L. ; Higashida, Jean ; Silverman, Stuart L. ; Parhami, Nourollah ; Buxbaum, Joel ; Haakenson, Clair M. ; Ward, Richard H. ; Manaster, B. J. ; Anderson, Robert J. ; Ward, John R. ; Henderson, William G. / Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). In: Arthritis and Rheumatism. 1996 ; Vol. 39, No. 12. pp. 2021-2027.
@article{31f36494de8743bb8d1685113abe224f,
title = "Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome)",
abstract = "Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective in the treatment of reactive arthritis (ReA) that has been unresponsive to nonsteroidal antiinflammatory drug (NSAID) therapy. Methods. One hundred thirty-four patients with ReA who had failed to respond to NSAIDs were recruited from 19 clinics, randomized (double-blind) to receive either SSZ or placebo, and followed up for 36 weeks. The definition of treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed improvement in the patients taking SSZ compared with those taking placebo, which appeared at 4 weeks and continued through the trial (P = 0.02). At the end of treatment, response rates were 62.3{\%} for SSZ treatment compared with 47.7{\%} for placebo treatment. The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and effective in patients with chronically active ReA.",
author = "Clegg, {Daniel O.} and Reda, {Domenic J.} and Weisman, {Michael H.} and Cush, {John J.} and Vasey, {Frank B.} and Schumacher, {H. Ralph} and Elly Budiman-Mak and Balestra, {Dominic J.} and Blackburn, {Warren D.} and Cannon, {Grant W.} and Inman, {Robert D.} and Alepa, {F. Paul} and Edwin Mejias and Cohen, {Miriam R.} and Rama Makkena and Mahowald, {Maren L.} and Jean Higashida and Silverman, {Stuart L.} and Nourollah Parhami and Joel Buxbaum and Haakenson, {Clair M.} and Ward, {Richard H.} and Manaster, {B. J.} and Anderson, {Robert J.} and Ward, {John R.} and Henderson, {William G.}",
year = "1996",
month = "12",
language = "English (US)",
volume = "39",
pages = "2021--2027",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome)

AU - Clegg, Daniel O.

AU - Reda, Domenic J.

AU - Weisman, Michael H.

AU - Cush, John J.

AU - Vasey, Frank B.

AU - Schumacher, H. Ralph

AU - Budiman-Mak, Elly

AU - Balestra, Dominic J.

AU - Blackburn, Warren D.

AU - Cannon, Grant W.

AU - Inman, Robert D.

AU - Alepa, F. Paul

AU - Mejias, Edwin

AU - Cohen, Miriam R.

AU - Makkena, Rama

AU - Mahowald, Maren L.

AU - Higashida, Jean

AU - Silverman, Stuart L.

AU - Parhami, Nourollah

AU - Buxbaum, Joel

AU - Haakenson, Clair M.

AU - Ward, Richard H.

AU - Manaster, B. J.

AU - Anderson, Robert J.

AU - Ward, John R.

AU - Henderson, William G.

PY - 1996/12

Y1 - 1996/12

N2 - Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective in the treatment of reactive arthritis (ReA) that has been unresponsive to nonsteroidal antiinflammatory drug (NSAID) therapy. Methods. One hundred thirty-four patients with ReA who had failed to respond to NSAIDs were recruited from 19 clinics, randomized (double-blind) to receive either SSZ or placebo, and followed up for 36 weeks. The definition of treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed improvement in the patients taking SSZ compared with those taking placebo, which appeared at 4 weeks and continued through the trial (P = 0.02). At the end of treatment, response rates were 62.3% for SSZ treatment compared with 47.7% for placebo treatment. The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and effective in patients with chronically active ReA.

AB - Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective in the treatment of reactive arthritis (ReA) that has been unresponsive to nonsteroidal antiinflammatory drug (NSAID) therapy. Methods. One hundred thirty-four patients with ReA who had failed to respond to NSAIDs were recruited from 19 clinics, randomized (double-blind) to receive either SSZ or placebo, and followed up for 36 weeks. The definition of treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed improvement in the patients taking SSZ compared with those taking placebo, which appeared at 4 weeks and continued through the trial (P = 0.02). At the end of treatment, response rates were 62.3% for SSZ treatment compared with 47.7% for placebo treatment. The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and effective in patients with chronically active ReA.

UR - http://www.scopus.com/inward/record.url?scp=5544272676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5544272676&partnerID=8YFLogxK

M3 - Review article

C2 - 8961907

AN - SCOPUS:5544272676

VL - 39

SP - 2021

EP - 2027

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -